Investors & Media

Oct 24, 2020 /

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Oct 24, 2020 / Oct 24, 2020 /

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent News

10/22/20

BELLUS Health Closes US$40 Million Public Offering of Common Shares in Canada and the United States, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
LAVAL, Quebec --(BUSINESS WIRE)--Oct. 22, 2020-- BELLUS Health Inc. (NASDAQ: BLU)(TSX: BLU) (the “Company” or “BELLUS Health”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced...
Read More
10/19/20

BELLUS Health Announces Pricing of US$35 Million Public Offering in Canada and the United States
Common Shares Priced at US$2.25 per Share LAVAL, Quebec --(BUSINESS WIRE)--Oct. 19, 2020-- In connection with its previously announced public offering of common shares in Canada and the United States (the “Offering”), BELLUS Health Inc. (“BELLUS Health” or the “Company”) (TSX and Nasdaq: BLU) today...
Read More
10/19/20

BELLUS Health Announces the Launch of a Public Offering of Common Shares in Canada and the United States
LAVAL, Quebec --(BUSINESS WIRE)--Oct. 19, 2020-- BELLUS Health Inc. (“BELLUS Health” or the “Company”) (TSX and Nasdaq: BLU), announced today the filing of a preliminary prospectus supplement (the “Supplement”) to its short form base shelf prospectus dated January 17, 2020 (the “Base Prospectus”)...
Read More